Oculis Holding Ag (OCS)
NASDAQ:OCS
Want to see OCS full AI Analyst Report?
OCS Stock Chart & Stats
$27.46
$0.20(1.10%)
At close: 4:00 PM EST
$27.46
$0.20(1.10%)
Day’s Range― - ―
52-Week Range$13.81 - $34.48
Previous CloseN/A
Volume95.89K
Average Volume (3M)560.86K
Market Cap
$702.61M
Enterprise Value$949.95M
Total Cash (Recent Filing)$221.37M
Total Debt (Recent Filing)$2.24M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 06, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding57,169,476
10 Day Avg. Volume655,449
30 Day Avg. Volume560,857
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue1.88K
Enterprise Value/Gross Profit-65.23
Enterprise Value/Ebitda-11.21
Forecast
1Y Price Target
$38.30Price Target Upside39.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$787.01K
Bulls Say, Bears Say
Bulls Say
Strong Liquidity PositionLarge cash plus significant short-term financial assets create a multi-year funding buffer to complete ongoing registrational trials and meet near-term operating needs. This liquidity reduces immediate refinancing pressure, allowing management to prioritize clinical milestones rather than urgent capital raises.
Very Low Leverage / Solid Equity BaseExtremely low debt and a sizable equity cushion give the company financial flexibility to fund R&D and absorb development setbacks. Low leverage reduces fixed financing costs and preserves optionality to raise capital on more favorable terms, strengthening balance-sheet resilience over the medium term.
Advanced Pipeline With Regulatory ProgressMultiple late-stage and registrational programs, including an FDA Breakthrough Therapy designation and completed Phase 3 enrollment, materially increase the probability of near-to-medium-term approvals. Diversified clinical assets across ophthalmology reduce binary risk and position the company to access large addressable markets if trials succeed.
Bears Say
Sustained Large Losses And Cash BurnConsistent high R&D and operating losses drive meaningful negative cash flow, necessitating ongoing external funding until revenue materializes. Prolonged burn increases execution risk, could constrain strategic choices, and makes the timeline to break-even dependent on successful clinical outcomes and commercialization.
Minimal Commercialization / RevenueNegligible revenue indicates the company remains pre-commercial and reliant on trial success for sustainable income. Without operating revenue, the business cannot self-fund growth or absorb higher spending, leaving long-term viability contingent on approvals and successful market launches.
Ongoing Reliance On Equity MarketsActive ATM capacity and prior equity financings signal structural dependence on capital markets to fund operations. Continued issuance programs raise dilution risk and may pressure shareholder value over time, especially if clinical readouts are delayed or require further rounds of financing.
Oculis Holding News
OCS FAQ
What was Oculis Holding Ag’s price range in the past 12 months?
Oculis Holding Ag lowest stock price was $13.80 and its highest was $34.48 in the past 12 months.
What is Oculis Holding Ag’s market cap?
Oculis Holding Ag’s market cap is $702.61M.
When is Oculis Holding Ag’s upcoming earnings report date?
Oculis Holding Ag’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Oculis Holding Ag’s earnings last quarter?
Oculis Holding Ag released its earnings results on May 11, 2026. The company reported -$0.621 earnings per share for the quarter, missing the consensus estimate of -$0.507 by -$0.114.
Is Oculis Holding Ag overvalued?
According to Wall Street analysts Oculis Holding Ag’s price is currently Undervalued.
Does Oculis Holding Ag pay dividends?
Oculis Holding Ag does not currently pay dividends.
What is Oculis Holding Ag’s EPS estimate?
Oculis Holding Ag’s EPS estimate is -0.5.
How many shares outstanding does Oculis Holding Ag have?
Oculis Holding Ag has 57,169,476 shares outstanding.
What happened to Oculis Holding Ag’s price movement after its last earnings report?
Oculis Holding Ag reported an EPS of -$0.621 in its last earnings report, missing expectations of -$0.507. Following the earnings report the stock price went down -6.861%.
Which hedge fund is a major shareholder of Oculis Holding Ag?
Currently, no hedge funds are holding shares in OCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oculis Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.30 (39.48% Upside)
$38.30 (39.48% Upside)
Blogger Sentiment
Bullish
OCS Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Bearish
Bullish news 39%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.05%
12-Months-Change
Fundamentals
Return on Equity
-57.09%
Trailing 12-Months
Asset Growth
31.58%
Trailing 12-Months
Company Description
Oculis Holding Ag
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
OCS Stock 12 Month Forecast
Average Price Target
$38.30
▲(39.48% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Spyre Therapeutics
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Upstream Bio, Inc.
―
Ownership Overview
―
Insiders
1.58% Mutual Funds
26.35% Other Institutional Investors
71.76% Public Companies and
Individual Investors